Purple Biotech ADR

Purple Biotech reports that IM1240 was effective in preclinical tests at the Icahn School of Medicine in all seven patient-derived tumor samples tested, including therapy‑resistant cases of head and neck squamous cell carcinoma and muscle‑invasive bladder carcinoma. The NKG2A component enhanced anti-tumor activity; a mutated NKG2A domain resulted in loss of apoptotic activity. Tissue analyses showed induction of tertiary lymphoid structures, an increase in CD8+ and NK cells, and a decrease in regulatory T cells and tumor cells. The company has a small market capitalization of about USD 6.24 million and is burning cash rapidly because of its pipeline. » Más en de.investing.com

Purple Biotech reported for the quarter ended December 31, 2025 a loss per share of $201.25, compared with -$1.59 in the year-ago quarter. For the fiscal year, the company reported EPS of -$54.43, after -$8,922.15 a year earlier. The announcement was presented at a financial conference on March 13, 2026. » Más en finanzen.net

Purple Biotech announced that CEO Gil Efron will step down from his CEO role in August 2026 for health reasons, move to corporate development and remain on the board. The company has launched a formal search for a successor and is seeking an experienced leader to advance the trispecific CAPTN‑3 platform. The stock is trading near its 52‑week low; market capitalization is about $5.93 million and analysis shows the company is burning cash quickly but has more cash than debt. Leading drug candidates include IM1240 and IM1305 in preclinical development. » Más en de.investing.com